Shares of Myovant Sciences Ltd. (MYOV) are rising over 4% in pre-market today, after the company announced that SPIRIT 2, the first of two Phase 3 studies of once-daily relugolix combination therapy in women with pain associated with endometriosis, met its co-primary efficacy endpoints and six key secondary endpoints.
from RTT - Before the Bell https://ift.tt/2VwKqjD
via IFTTT
No comments:
Post a Comment